Immuneering (IMRX) Projected to Post Earnings on Tuesday

Immuneering (NASDAQ:IMRX) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect Immuneering to post earnings of ($0.41) per share for the quarter.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.16). On average, analysts expect Immuneering to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immuneering Stock Performance

NASDAQ IMRX opened at $1.24 on Friday. Immuneering has a one year low of $1.00 and a one year high of $3.83. The firm has a 50 day simple moving average of $1.47 and a 200-day simple moving average of $1.82. The firm has a market cap of $44.62 million, a price-to-earnings ratio of -0.63 and a beta of -0.25.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Chardan Capital restated a “buy” rating and issued a $13.00 price target on shares of Immuneering in a research note on Monday, March 24th. Needham & Company LLC reissued a “buy” rating and set a $12.00 target price on shares of Immuneering in a research note on Thursday, April 10th.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.